3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasms
3
HER2-positive Breast Cancer
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Interventions
Specimen Handling
4
Biopsy
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Busulfan
2
venetoclax
1
tocilizumab
1
ruxolitinib
1
peginterferon alfa-2b
1
iadademstat
1
fludarabine
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Idarubicin
1
Hyperbaric Oxygenation
1
Filgrastim
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
pertuzumab
×
30 days
×
Clear all
No trials found.